LivaNova stock hits 52-week high at 84.3 USD
LivaNova PLC's stock reached a new 52-week high of $84.30, demonstrating an 81% total return over the past year. The company also announced promising data from its PolySync algorithm for sleep apnea and made several strategic leadership appointments and board additions. InvestingPro analysis suggests the stock remains undervalued despite its recent surge.
LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study
LivaNova Plc announced positive 12-month results from its OSPREY randomized controlled trial (RCT) for the aura6000 System, demonstrating the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS) in treating moderate to severe obstructive sleep apnea (OSA). The study found clinically significant and sustained improvements in AHI, sleep quality, and patient-reported outcomes. LivaNova received FDA premarket approval for the system and plans to commercialize its next-generation MRI-compatible device with a long-lasting rechargeable battery next year.
LivaNova PLC(NasdaqGS: LIVN) added to Russell Small Cap Comp Growth Benchmark
LivaNova PLC (NasdaqGS: LIVN), a medical technology company specializing in cardiopulmonary and neuromodulation products, has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion was formalized on June 29, 2026, alongside its addition to several other Russell major benchmarks. The company's stock closed at $83.06 on June 29, 2026.
LivaNova PLC(NasdaqGS: LIVN) added to Russell 2000 Growth Benchmark
LivaNova PLC (NasdaqGS: LIVN), a medical technology company, has been added to the Russell 2000 Growth Benchmark. The company designs, develops, manufactures, markets, and sells products and therapies across its Cardiopulmonary and Neuromodulation segments. This inclusion highlights its growth trajectory within the market.
LivaNova PLC(NasdaqGS: LIVN) added to Russell 3000 Growth Benchmark
LivaNova PLC (NasdaqGS: LIVN) was added to the Russell 3000 Growth Benchmark on June 28, 2026. The company is a medical technology firm specializing in cardiopulmonary and neuromodulation products and therapies. LivaNova has also been added to other Russell benchmarks, including the Russell Small Cap Comp Growth, Russell 2000 Growth, and Russell 2500 Growth.
(LIVN) Risk Channels and Responsive Allocation
This article analyzes Livanova Plc (LIVN) using AI models, identifying strong sentiment across all horizons supporting an overweight bias. It provides institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for near, mid, and long-term outlooks. The analysis highlights compelling upside potential for LIVN based on current signals and lack of resistance levels.
Livanova PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
This page provides financial actuals and estimates for Livanova PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (L2IV34) traded on BMFBOVESPA. Users can explore reported financial data and analyst estimates for income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates and visualizing trends over time. The platform explicitly states that the information is not investment advice and encourages users to do their own research.
LivaNova Plc Actuals & Estimates (NASDAQ:LIVN)
This article provides an overview of LivaNova PLC (NASDAQ: LIVN) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates for the company's income statement, balance sheet, and cash flow, alongside answers to frequently asked questions about its stock performance, market capitalization, earnings, and dividend policy.
LIVN Forecast — Price Target — Prediction for 2027
This article provides a forecast for LivaNova PLC (LIVN) stock, including analyst price targets, historical stock performance, and expected earnings and revenue. It details the current stock price, market capitalization, and key financial metrics, while also addressing frequently asked questions about investing in LIVN. The piece concludes with a recommendation for comprehensive research before investment and mentions the stock's current "buy" rating based on technical analysis.
LivaNova stock hits 52-week high at 81.08 USD By Investing.com
LivaNova PLC's stock reached a new 52-week high of $81.08, reflecting a 74% increase over the past year. The company's recent Q1 2026 earnings surpassed analyst expectations, and it has announced strategic leadership changes. InvestingPro analysis suggests the stock, currently trading at $80.86, is undervalued.
LIA Forecast — Price Target — Prediction for 2027
This article provides a forecast for LivaNova Plc (LIA) stock, including analyst price targets, ratings, and financial data. It details the company's past earnings and revenue, future estimates, and historical stock performance. The article also answers frequently asked questions about LIA, such as its ticker, dividend policy, employee count, and how to buy its stocks.
How New OSA PolySync Data Could Shape LivaNova’s (LIVN) Neuromodulation Investment Narrative
LivaNova (LIVN) recently presented new clinical data for its PolySync programming algorithm, showing an 84.5% response rate in moderate to severe Obstructive Sleep Apnea patients. This data reinforces the company's neuromodulation platform and its investment in next-generation OSA devices. While the Q2 2026 results on August 5 will provide an update on overall growth and spending, the PolySync data strengthens the investment narrative, with a key near-term catalyst being the planned 2026 FDA PMA supplement for the aura6000 device.
Press Release: LivaNova to Announce Second-Quarter 2026 Results
LivaNova (NASDAQ: LIVN) is scheduled to announce its second-quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. The company will host a conference call and webcast on Wednesday, August 5, 2026, at 9:00 a.m. EDT to discuss these results.
LivaNova to Announce Second-Quarter 2026 Results
LivaNova PLC (Nasdaq: LIVN) will host a conference call on Wednesday, August 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time) to discuss its second-quarter 2026 financial results. The company plans to release its results prior to the call, which will be accessible via audiocast on its website at www.livanova.com/events. A replay will also be available on the Investors section of the LivaNova website immediately after the event.
LivaNova PLC (LIVN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides detailed shareholder information for LivaNova PLC (LIVN), outlining its major institutional holders and their respective proportions. It also presents data on shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings for key investors. Additionally, it lists ETFs that have LIVN as a component.
LivaNova (LIVN) director logs RSU vesting, tax withholding and new 2027 RSU grant
LivaNova PLC director Peter M. Wilver reported routine equity compensation activity, including the vesting of 4,042 Restricted Stock Units (RSUs) and the withholding of 486 ordinary shares for tax liabilities at $79.70 per share. Following these transactions, he holds 10,294 ordinary shares directly. Additionally, Wilver received a new grant of 2,383 RSUs set to vest on June 15, 2027.
LivaNova (LIVN) director logs RSU vesting, tax withholding and new grant
LivaNova PLC director Susan M. Podlogar reported recent compensation-related share activity. This included the vesting of 4,042 restricted stock units (RSUs) into ordinary shares, with 486 shares withheld for tax liabilities at $79.70 per share. Additionally, Podlogar received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan, scheduled to vest in June 2027.
LivaNova PLC (LIVN) Financial Health: Profitability & Balance Sheet Analysis
LivaNova PLC (LIVN) has a robust financial score of 7.99, ranking 46 out of 204 in the Healthcare Equipment & Supplies industry. The company demonstrated strong operating efficiency with a 14.33% year-over-year revenue increase to $362.26M, and a significant 106.81% year-over-year net profit increase. Key financial indicators like cash and cash equivalents, total assets, and free cash flow underscore its healthy financial standing.
LivaNova PLC (LIVN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of LivaNova PLC (LIVN), noting its current valuation score of 6.22, ranking 190 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of 39.70 and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
LivaNova PLC (LIVN) Institutional Confidence
LivaNova PLC (LIVN) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 110.12%, showing a quarter-over-quarter increase of 3.56%. HOTCHKIS & WILEY is the largest institutional shareholder, holding 478.62K shares, which represents 1.01% of the shares outstanding.
LIVN SEC Filings - Livanova Plc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Livanova Plc (LIVN) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details recent filings with AI-generated summaries, impact scoring, and sentiment analysis for key financial results and corporate governance changes. Noteworthy recent filings include Q3 2025 earnings showing revenue growth but a net loss due to a significant environmental liability, and insider transaction details.
LivaNova (LIVN) director reports RSU vesting, tax withholding and new grant
LivaNova PLC director Barry James Christopher reported equity compensation activity, including the vesting of 4,042 Restricted Stock Units (RSUs) which converted into ordinary shares. A total of 486 shares were withheld for tax liabilities, and he received a new grant of 2,383 RSUs scheduled to vest on June 15, 2027. These transactions are routine equity compensation events and do not involve open-market purchases or sales.
LivaNova PLC (LIVN) director trades shares, receives 2,383 new RSUs
LivaNova PLC director Francesco Bianchi reported selling 1,200 ordinary shares at $80.19 each and having 4,042 restricted stock units (RSUs) vest, with 486 shares withheld for tax liabilities. He also received a new grant of 2,383 RSUs, which are set to vest on June 15, 2027. After these transactions, Bianchi directly holds 9,584 LivaNova ordinary shares.
[Form 4] LivaNova PLC Insider Trading Activity
LivaNova PLC director Todd C. Schermerhorn reported recent equity activity, including the exercise of 4,042 Restricted Stock Units (RSUs) into ordinary shares and the withholding of 486 shares for tax liabilities. He also received a new grant of 2,383 RSUs that will vest in June 2027. This activity is compensation-related and not an open-market sale, maintaining a neutral filing impact and sentiment for the company.
LivaNova (LIVN) director logs RSU vesting, tax withholding and new 2027 grant
LivaNova PLC director Donald Zurbay reported equity compensation activity, including the settlement of 2,560 vested Restricted Stock Units (RSUs) into ordinary shares to cover tax obligations. After withholding 308 shares for taxes, Zurbay directly holds 2,252 ordinary shares. Additionally, he received a new grant of 2,383 RSUs set to vest on June 15, 2027, subject to continued service.
LivaNova Reports Improved OSA Outcomes With PolySync Programming
LivaNova announced new data from its PolySync substudy demonstrating significantly improved outcomes for patients with moderate-to-severe Obstructive Sleep Apnea (OSA) treated with its aura6000 System. The PolySync algorithm increased the cumulative apnea-hypopnea index (AHI) response rate from 65% to 84.5%, strengthening LivaNova's position in the sleep apnea market. The company is also developing a next-generation OSA device with planned submission in the second half of 2026.
LivaNova’s programming algorithm boosts response rates in sleep apnoea patients
New data from LivaNova's OSPREY trial demonstrated that its proprietary PolySync programming algorithm significantly increased the response rate for obstructive sleep apnoea (OSA) patients undergoing proximal hypoglossal nerve stimulation (p-HGNS) treatment to 84.5%. This algorithm, used with the aura6000 system, helps reconfigure stimulation fields, converting non-responders into responders. LivaNova aims for a US market launch of the aura6000 system in 2027.
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
LivaNova PLC announced new data from its OSPREY study, presented at SLEEP 2026, showing that its PolySync programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) treated with proximal hypoglossal nerve stimulation (pHGNS). This improvement was achieved by converting non-responders into responders through simultaneous-contact stimulation, significantly enhancing AHI and oxygen desaturation index (ODI) outcomes. The company plans to integrate PolySync into its commercial pHGNS product and is preparing for a PMA supplement application for its next-generation MRI-compatible OSA device in late 2026.
LIVANOVA reports 84.5% response rate with PolySync in sleep apnea study
LivaNova PLC announced new data from its PolySync programming algorithm, showing an 84.5% cumulative apnea-hypopnea index (AHI) response rate in patients with moderate to severe obstructive sleep apnea (OSA). This improved response was achieved by converting non-responders to responders using simultaneous-contact stimulation, building on the 65% responder rate from the OSPREY trial. The company plans to integrate PolySync into its commercial pHGNS product and submit a premarket approval supplement for a next-generation OSA device to the FDA in the latter half of 2026.
LivaNova sleep apnea therapy shows 84.5% response rate with new algorithm
LivaNova presented data at SLEEP 2026 demonstrating that its PolySync programming algorithm achieved an 84.5% response rate in patients with moderate to severe obstructive sleep apnea (OSA) treated with proximal hypoglossal nerve stimulation. The company's shares have seen a 75% return over the past year, and PolySync will be integrated into its commercial proximal hypoglossal nerve stimulation product, with the next-generation device expected for a PMA supplement application in H2 2026. InvestingPro analysis suggests the stock is marginally overvalued, though analysts are optimistic.
(LIVN) Movement As An Input In Quant Signal Sets
This article from Stock Traders Daily analyzes Livanova Plc (NASDAQ: LIVN) using AI-generated quantitative signals. It highlights strong sentiment across all horizons, suggesting an overweight bias, and provides specific institutional trading strategies including position, momentum breakout, and risk hedging with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for near-term, mid-term, and long-term horizons.
LivaNova PLC (NASDAQ: LIVN) insider sells 1,800 shares for $136,350
LivaNova PLC reported a Form 144 notice detailing an insider sale of 1,800 shares of common stock by Francesco Bianchi on May 26, 2026, for $136,350. The filing also disclosed vesting events of restricted stock units on June 15, 2024, and June 29, 2021, granted under the company's equity compensation plan. The total common stock figure was noted as 54,933,538 as of June 15, 2026.
Is LivaNova’s (LIVN) Boardroom Refresh Quietly Reframing Its Long-Term Risk and Strategy Playbook?
LivaNova PLC recently made significant boardroom changes, electing Jette Nygaard-Andersen and appointing Anne Liddy as Chief Legal Officer, while long-serving director Dr. Sharon O’Kane stepped down. These appointments are expected to enhance LivaNova's governance, especially regarding global healthcare regulations and compliance. The article suggests these changes primarily strengthen oversight without immediately altering core business catalysts or risks, though the new leadership could influence regulatory timelines and cost pressures.
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
LivaNova PLC announced the election of Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting. Nygaard-Andersen brings extensive experience in medtech governance, CEO leadership, strategic M&A, and digital innovation. Concurrently, Dr. Sharon O’Kane stepped down from the Board, and new committee leadership roles were announced for Brooke Story, Peter Wilver, and Todd Schermerhorn.
Jette Nygaard-Andersen named director of LivaNova board
LivaNova PLC has appointed Jette Nygaard-Andersen to its Board of Directors, a decision made after its Annual General Meeting on June 10. Nygaard-Andersen brings extensive experience in medtech governance, CEO leadership, and strategic M&A across global businesses, having previously served as Chair of Coloplast A/S and CEO of Entain plc. Concurrently, Dr. Sharon O’Kane stepped down from the Board after over a decade of service.
LivaNova adds Jette Nygaard-Andersen to board of directors
LivaNova PLC has announced the appointment of Jette Nygaard-Andersen to its board of directors following the annual general meeting. Nygaard-Andersen, who chairs Coloplast A/S's board and previously served as CEO of Entain plc, brings extensive experience in medical devices, media, entertainment, and gaming. Her appointment coincides with other board changes, including the departure of Dr. Sharon O’Kane, and follows LivaNova's strong financial performance with increasing net income and recent robust Q1 2026 earnings.
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
LivaNova PLC has announced the election of Jette Nygaard-Andersen to its Board of Directors, following the annual general meeting on June 10. Ms. Nygaard-Andersen brings extensive experience in medtech governance, CEO leadership, and digital innovation, currently serving as Chair of Coloplast A/S. Concurrently, Dr. Sharon O’Kane stepped down from the Board after over a decade of service, with Brooke Story succeeding her as Chair of the Nominating and Corporate Governance Committee.
LivaNova stock hits 52-week high at 76.92 USD By Investing.com
LivaNova stock reached a 52-week high of $76.92, currently trading at $74.80 with a market capitalization of $4.11 billion. The stock has shown a significant 61.56% return over the past year and is considered undervalued by InvestingPro Fair Value analysis. This performance follows strong Q1 2026 earnings, which surpassed analyst expectations, and recent strategic personnel appointments.
LivaNova stock hits 52-week high at 76.92 USD
LivaNova (LIVN) stock reached a new 52-week high of $76.92, currently trading at $74.80 with a market capitalization of $4.11 billion. This performance is supported by strong Q1 2026 earnings, which surpassed analyst expectations in both adjusted EPS and revenue. The company also announced key personnel changes in its legal and cardiopulmonary departments.
LivaNova PLC (LIVN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100
LivaNova PLC (LIVN) stock rose 3.4% to $74.80, but GuruFocus's GF Value indicates it is 20.0% overvalued at $62.31. Despite a GF Score of 77/100, showing overall strong performance, recent insider selling suggests caution. Investors are advised to wait for a price adjustment closer to its intrinsic value.
LIVN - LivaNova PLC Stock Price and Quote
This article provides a detailed stock price and quote for LivaNova PLC (LIVN), a global medical technology company. It includes comprehensive financial data, market performance metrics, recent analyst ratings, and a list of insider transactions. The company's business segments, key executives, and recent news announcements are also highlighted.
LivaNova beats estimates but shares fall 2% on guidance concerns
LivaNova plc (NASDAQ:LIVN) reported strong first-quarter results, exceeding Wall Street expectations for both adjusted earnings per share and revenue. Despite raising its full-year revenue and adjusted EPS guidance, the stock fell over 2% in pre-market trading, likely due to the midpoint of the new EPS guidance being only slightly above consensus estimates. The medical technology company saw significant growth in its Cardiopulmonary and Neuromodulation segments, and achieved a key regulatory milestone with FDA approval for its aura6000 System for obstructive sleep apnea.
LivaNova names Anne Liddy as chief legal officer
LivaNova PLC has appointed Anne Liddy as its new Chief Legal Officer, effective August 31, where she will oversee global legal and compliance functions and join the Executive Leadership Team. Liddy brings over 20 years of legal and compliance experience in the healthcare and life sciences sectors, previously serving as General Counsel at Hologic, Inc. This leadership addition comes as the medical technology company, valued at $4.05 billion, is trading near its 52-week high and is considered undervalued by InvestingPro analysis, following a strong Q1 2026 performance.
LivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova PLC has announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31, where she will oversee the company's global legal and compliance functions and join the Executive Leadership Team. Liddy brings over two decades of experience from Hologic, Inc. and Pfizer, Inc., specializing in legal, regulatory, M&A, and compliance matters for healthcare and life sciences companies. CEO Vladimir Makatsaria highlighted Liddy's expertise and leadership as instrumental in advancing LivaNova's business and innovation goals.
LivaNova Q1 2026 slides: double-digit growth drives guidance raise
LivaNova (NASDAQ:LIVN) reported strong first-quarter 2026 results, surpassing analyst expectations with adjusted EPS of $0.98 and revenue of $362.3 million. This performance, driven by double-digit growth in both Cardiopulmonary and Neuromodulation segments and the FDA approval of its aura6000 System for obstructive sleep apnea, led the company to raise its full-year 2026 guidance. Investors responded positively, with shares increasing over 6% in premarket trading.
Did LivaNova's (LIVN) New Cardiopulmonary Chief from Philips Just Redefine Its Leadership Bench?
LivaNova PLC announced the appointment of Stefano Folli from Philips as the new President of its Cardiopulmonary business, effective June 1, 2026, succeeding Franco Poletti after a transition period. This leadership change is viewed as a continuity move, with investors focusing on Folli's impact on the Essenz Perfusion System and the broader cardiopulmonary business, alongside the commercialization of the aura6000 System for obstructive sleep apnea. The article suggests that while some analysts have bullish outlooks for LivaNova's revenue and earnings, the effectiveness of Folli's leadership in the CP business will be crucial for validating current valuations against potential pricing and reimbursement pressures.
Did LivaNova's (LIVN) New Cardiopulmonary Chief from Philips Just Redefine Its Leadership Bench?
LivaNova PLC announced that Stefano Folli will join the company as the incoming President of its Cardiopulmonary business on June 1, 2026, succeeding Franco Poletti after a transition period. Folli, a veteran from Philips, is expected to influence LivaNova's cardiopulmonary portfolio, including the Essenz Perfusion System. Investors will be watching how he shapes the business alongside the commercialization of the aura6000 System for obstructive sleep apnea to see if growth can justify current valuation, amidst potential pricing and reimbursement pressures.
LivaNova (LIVN) director Bianchi sells 1,800 shares in open-market trade
LivaNova director Francesco Bianchi sold 1,800 Ordinary Shares in an open-market transaction on May 26, 2026, at an average price of $75.75 per share, totaling $136,350. Following this sale, Bianchi directly holds 7,228 Ordinary Shares of LivaNova. This transaction was reported on a Form 4 filing, indicating a moderate filing impact and negative sentiment for the company.
LivaNova (LIVN) files Form 144; Merrill Lynch listed for proposed sale
LivaNova PLC has filed a Form 144 notice, indicating a proposed sale of Common Stock with Merrill Lynch listed as the broker and a trade date of May 26, 2026. The filing references previous restricted stock unit vesting events and includes numeric entries related to securities, though explicit labels for these figures are not provided. Form 144 is a required notice for affiliates selling restricted or control securities under Rule 144.
LivaNova Plc Hits New 52-Week High at USD 74.28
LivaNova Plc has reached a new 52-week high of USD 74.28, showcasing a strong performance with a 39.8% return over the past year, outperforming the S&P 500. The company, a small-cap in pharmaceuticals and biotechnology, has a market cap of USD 3,391 million and has demonstrated resilience in operational cash flow and improved inventory management despite negative equity and high debt.
